Format

Send to

Choose Destination
World J Gastroenterol. 2013 Feb 28;19(8):1318-21. doi: 10.3748/wjg.v19.i8.1318.

Hepatitis B reactivation in chronic myeloid leukemia patients receiving tyrosine kinase inhibitor.

Author information

1
Division of Hemato-Oncology, Department of Internal Medicine, Changhua Christian Hospital, Changhua 500, Taiwan.

Abstract

Hepatitis B virus (HBV) reactivation is a well-recognized complication in patients with chronic HBV infection receiving cytotoxic or immunosuppressive chemotherapy. Imatinib mesylate and nilotinib are selective Bcr/Abl tyrosine kinase inhibitors, which are now widely used in the treatment of patients with chronic myeloid leukemia. Although HBV reactivation induced by imatinib mesylate has been reported, nilotinib-related HBV reactivation has not been reported in the English literature. We report here 2 cases of HBV reactivation in chronic myeloid leukemia patients receiving imatinib mesylate and a novel case of nilotinib related HBV reactivation.

KEYWORDS:

Chronic myeloid leukemia; Hepatitis B virus; Imatinib mesylate; Nilotinib; Tyrosine kinase inhibitor

PMID:
23483799
PMCID:
PMC3587491
DOI:
10.3748/wjg.v19.i8.1318
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Baishideng Publishing Group Inc. Icon for PubMed Central
Loading ...
Support Center